Abeona Therapeutics Inc.

ABEO

Healthcare Biotechnology

Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.

Revenue
+225.1%
EPS
−116.9%
Free cash flow
+17.1%
Total debt
−23.4%

Quarter to June 2026, against a year earlier

4.17 0.26 +6.65%
Market cap
$238.5M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
2.0×
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
3 4 3 — — — 2 3 — —
P/E ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 — 4.02
Altman Z-Score
4.08 43.26 1.14 — (4.76) (14.09) (16.52) (16.67) — (2.32)
P/S ratio
192.24 855.63 113.19 — 11.93 2.46 5.09 29.04 — 29.73
P/FCF ratio
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 — 0.00
Altman Z″-Score (non-manufacturers)
1.11 17.95 (3.84) — (11.29) (29.98) (35.25) (38.47) — (5.75)
Beneish M-Score
(3.84) (2.64) (1.64) — — — (3.45) 1.67 — —
P/Operating CF
(50.37) (141.93) (20.00) — (90.36) (1.10) (1.61) (15.45) — (15.54)
P/B ratio
1.72 4.21 2.53 — 1.42 0.78 0.84 9.62 — 1.75
EV/Sales
118.96 695.84 86.18 — 4.42 (0.62) (5.07) 19.50 — 11.47
EV/EBITDA
0.00 0.00 0.00 — 0.00 0.09 0.48 0.00 — 0.00
EV/FCF
(7.81) (24.77) (5.34) — (1.48) 0.12 0.53 (2.58) — (1.28)
Current Ratio
8.37 25.07 4.37 3.42 2.33 3.39 6.83 4.15 6.08 6.93
Net Debt/EBITDA
3.00 5.08 1.52 1.75 1.21 0.49 0.97 1.20 1.29 2.00
Debt/Equity
0.00 0.00 0.00 0.04 0.03 0.22 0.29 0.00 0.43 0.13
ROE
(26.22%) (20.30%) (37.27%) (48.82%) (59.96%) (117.22%) (125.79%) (260.60%) (216.57%) 70.05%
ROA
(22.89%) (18.85%) (32.09%) (38.35%) (44.98%) (73.61%) (60.47%) (84.53%) (73.71%) 43.34%
ROIC
(49.83%) (53.78%) (74.07%) (84.35%) (463.12%) (6,756.62%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(35.37%) (20.03%) (72.71%) (71.39%) (125.53%) (163.31%) (85.15%) (118.19%) (71.86%) 38.42%
Average Days of Receivables
50.91 46.66 9.86 — 0.00 365.00 48.53 254.87 0.00 421.13
Earnings Yield
(12.80%) (3.84%) (15.83%) — (57.96%) (252.08%) (213.97%) (46.65%) — 24.86%
Free Cash Flow Yield
(7.92%) (3.28%) (14.25%) — (24.99%) (210.31%) (186.25%) (26.03%) — (30.21%)
Free Cash Flow per Share
(9.90) (14.12) (25.43) (34.32) (9.81) (17.73) (5.33) (1.74) (1.42) (1.59)
Book value per Share
72.48 102.13 70.51 88.59 27.67 10.76 3.40 0.69 1.07 3.01
Free Cash Flow
(13.53) (23.51) (48.35) (69.13) (36.35) (69.82) (41.88) (37.14) (58.44) (84.30)
EV/EBIT
0.00 0.00 0.00 — 0.00 0.09 0.44 0.00 — 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026